Latest News

By Diagnostic World Team  

May 29, 2025 | iCAD announced a collaboration with Microsoft to include a set of AI-powered mammography solutions; Revvity has launched its new IDS i20 analytical random access platform from EUROIMMUN; and more. 

Illumina announced the launch of DRAGEN version 4.4 software (v4.4). The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays. Additionally, DRAGEN v4.4 continues DRAGEN's best-in-class accuracy with a 30% improvement in germline structural variant calling accuracy. DRAGEN v4.4 enhancements will simplify NGS analysis for customers while expanding their capabilities. Press release.

Imec announced their collaboration with Massachusetts Institute of Technology (MIT). The collaboration aims to develop nanoelectronics-based, minimally-invasive diagnostic devices capable of monitoring biomarkers and vital signs in clinical, point-of-care, or home settings. When combined with AI, these data enable the creation of an individual’s digital biological profile that can facilitate detailed clinical monitoring. This provides clinicians with powerful tools for therapy, diagnosis, and prevention of diseases, ultimately enhancing quality of life. Press release.

SIME Diagnostics announced the completion of a clinical study evaluating an AI-powered Lung Maturity Test (LMT) for late-preterm newborns in a US patient population. The findings were presented by Mayo Clinic’s Rochester Neonatal team at the Pediatric Academic Societies (PAS) 2025 Conference. This first-of-its-kind platform consists of a point-of-care device and single-use cartridge that rapidly analyzes routinely collected samples without the need for reagents. The device enables real-time analysis of lung biochemistry by measuring key biomarkers—lecithin and sphingomyelin.  Press release.   

Revvity has launched its new IDS i20 analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The versatile IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer’s disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low-throughput analyzers, the IDS i20 platform offers labs a new means of more flexible, fully automated ChLIA processing. The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. Press release.

Using the gene scissors CRISPR and stem cells, researchers at Stockholm University and the UK Dementia Research Institute (UK DRI) at King's College London have managed to identify a common denominator for different gene mutations that all cause the neurological disease ALS. The research shows that ALS-linked dysfunction occurs in the energy factories of nerve cells, the mitochondria, before the cells show other signs of disease, which was not previously known. The research team was able to establish that these problems were common to all ALS-caused mutations, which will be important for future treatments of the disease. Press release.

Rady Children’s Institute for Genomic Medicine (RCIGM) has announced a partnership with Alexion, AstraZeneca Rare Disease, which has now become the inaugural Platinum member of the BeginNGS Consortium. This milestone builds upon nearly a decade of prior collaboration, reflecting a shared commitment to accelerating innovation in the realm of rare genetic disease diagnostics. The Consortium is positioned to transform newborn screening through the integration of whole genome sequencing (WGS), setting a new standard for early and precise detection of hundreds of serious childhood genetic conditions worldwide. Press release.

In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of California Los Angeles, and the Veterans Affairs (VA) National Precision Oncology Program found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care. The study, published in JAMA Network Open, analyzed data from more than 5,000 U.S. veterans with metastatic prostate cancer who underwent next-generation sequencing between 2019 and 2023. It found that while non-Hispanic Black veterans had higher rates of actionable immunotherapy targets, non-Hispanic white veterans had more frequent alterations in androgen receptor signaling and DNA repair pathways. Despite these biological differences, survival outcomes were comparable in the equal-access VA setting. Press release. 

Mass General Brigham developed a deep learning algorithm called FaceAge that uses a photo of a person’s face to predict biological age and survival outcomes for patients with cancer. They found that patients with cancer, on average, had a higher FaceAge than those without and appeared about five years older than their chronological age. Older FaceAge predictions were associated with worse overall survival outcomes across multiple cancer types. They also found that FaceAge outperformed clinicians in predicting short-term life expectancies of patients receiving palliative radiotherapy. The results were published in The Lancet Digital Health. Press release.

QIAGEN has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digital Insights (QDI) portfolio. Press release.

datma announced the launch of advanced patient journey mapping capabilities within its flagship platform, datma.FED. Designed to provide pharmaceutical companies with a clearer view of how therapies are adopted in real-world care, this new functionality enables structured, privacy-preserving analysis of patient timelines across clinical, genomic, and diagnostic data. Press release.

Sapient has launched the next generation of its multi-omics and real-world data (RWD) human biology database, now branded as the DynamiQ Insights Engine, which increases the speed, versatility, and depth of analyses that Sapient can perform to inform drug discovery and precision drug development strategies. DynamiQ features an expanded data lakehouse infrastructure, developed in collaboration with Sapient’s partner Rancho Biosciences, that enables rapid curation of Sapient’s unique datasets comprising thousands of protein, metabolite, lipid, and cytokine measures per sample alongside matched genomic and RWD including electronic health records (EHR), lab measures, and clinical outcomes. Press release.